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REVIEW
Abstract: Anticoagulant therapy is effective at preventing the development of venous
thromboembolism in high-risk patients, and reduces morbidity and mortality in individuals
with established thromboembolic disease. Vitamin K antagonists and heparins are currently
the most commonly used anticoagulant drugs, but they have practical limitations. Therefore,
new antithrombotic agents with predictable dose-responses (thereby decreasing the need for
monitoring without compromising efficacy or safety), ideally available in an oral formulation
and with a rapidly reversible anticoagulant effect, are needed. New drugs fulfilling some of
the above criteria have been developed and have proven to be effective agents for the treatment
and prevention of venous thromboembolism.
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Introduction
Venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and
pulmonary embolism (PE), is a common and potentially fatal disease with an annual
incidence of 0.1% in Caucasian populations (White 2003). Effective antithrombotic
therapy has been shown to reduce mortality in patients with PE (Barritt and Jordan
1960) and to reduce extension and recurrence in patients with proximal or distal
DVT (Lagerstedt et al 1985; Hull et al 1986). Antithrombotic agents have also been
shown to reduce the risk of VTE in a wide variety of high-risk situations, although,
despite prophylaxis, the incidence of venous thrombosis is still high in some
circumstances such as following major orthopedic surgery (Geerts et al 2001). Despite
the proven efficacy of currently available anticoagulants in most situations, limitations
of the same drugs continue to complicate their practical use in real life. This has
driven the search for new antithrombotic agents that maintain (or improve) efficacy
and safety, but that are more convenient to use.
The balance between normal hemostasis and thrombosis is determined by the
interaction of numerous individual pro- and anticoagulant factors, increased
knowledge of which has enabled identification of novel therapeutic targets (Figure 1).
Tissue factor is the trigger initiating normal hemostasis, but if excessive amounts are
released, it can also cause venous and arterial thrombosis (Davie 1995). During the
initiation stage of coagulation, tissue factor in the presence of calcium binds to
activated factor VII (FVIIa) to form the extrinsic tenase complex, which activates
FX and FIX. By itself, the initially produced FXa bound to phospholipid converts
small amounts of prothrombin to thrombin inefficiently (Mann et al 2003), with the
thrombin produced then feeding back to activate FV, FVIII, and FXI, and also initiating
platelet activation. This allows formation of intrinsic tenase and prothrombinase
complexes on the surface of activated platelets, with the cofactors FVa and FVIIIa
optimizing the interaction of the enzyme complexes with their target proteins, resulting
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in highly efficient activation of FX and prothrombin,
respectively. Rapid production of thrombin and clot
formation then result (Mann et al 2003).
This explosive process is kept in check by a number of
regulatory processes. The initiation phase is kept in check
by the stoichiometric inhibitor, tissue factor pathway
inhibitor (TFPI). This forms a quaternary complex with FX,
FVIIa, and tissue factor leading to their inactivation (Baugh
et al 1998). Thrombin also limits its own activation by
binding to thrombomodulin on the endothelial cell surface.
This limits its procoagulant activity and changes its substrate
specificity to the natural anticoagulant, protein C (Esmon
1989). In combination with its cofactor, protein S, activated
protein C inactivates FVa and FVIIIa, thereby attenuating
thrombin production.
Heparin and vitamin K antagonists, such as warfarin,
have long been the main weapons in the antithrombotic
armamentarium. Discovered in 1916, unfractionated heparin
(UFH) exerts its antithrombotic effect by binding to the
natural inhibitor antithrombin (AT), inducing a
conformational change that accelerates the rate at which
AT inactivates multiple coagulation enzymes (FIXa, FXa,
IIa) (Hirsh, Warkentin, et al 2001). UFH requires parenteral
administration, and due to variable non-specific binding to
plasma proteins, produces a variable anticoagulant response.
This non-specific protein binding also results in unwanted
side effects such as osteoporosis and heparin-induced
thrombocytopenia (HIT), a rare idiosyncratic prothrombotic
state due to the production of antiheparin antibodies (Hirsh,
Warkentin, et al 2001). Low molecular weight heparin
(LMWH) has more predictable pharmacokinetic properties,
and has largely replaced UFH for many indications.
However, LMWH still can cause HIT and, like UFH, has
the theoretical disadvantage of being unable to inactivate
thrombin bound to fibrin (Weitz and Crowther 2002).
Warfarin is the most widely used vitamin K antagonist
drug. Like UFH, it targets multiple steps in the coagulation
cascade, inhibiting the production of FII (prothrombin),
FVII, FIX, and FX (Hirsh, Dalen, et al 2001) Although
warfarin is convenient because it is orally administered, it
has an unpredictable anticoagulant effect and therefore
requires blood monitoring. It has a slow onset and offset of
action, and therefore requires the use of vitamin K and/or
plasma products in the event of bleeding (Hirsh, Dalen, et
al 2001).
Thus, all currently available anticoagulants have
limitations, and there is “room for improvement”.
Characteristics of the ideal anticoagulant agent include: (1)
a predictable anticoagulant effect; (2) a wide therapeutic
window (reducing the risk of bleeding and removing the
need for monitoring); (3) a rapid onset of action; (4) a rapid
offset of action and an available antidote; (5) oral
formulation; and (6) once or twice daily dosing (Hirsh et al
2005). In the last 10 years, numerous novel anticoagulant
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Figure 1 The coagulation cascade and sites of action of new drugs. Abbreviations: APC, activated protein C; DTI, direct thrombin inhibitors; PL, phospholipids; STM,
soluble thrombomodulin; TFPI, tissue factor pathway inhibitor.
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agents targeting specific steps in the coagulation pathway
(Figure 1) have been developed in an attempt to meet some
(or all) of the above criteria. It had been hoped that by
targeting specific rather than multiple steps, the risk of
bleeding associated with anticoagulant therapy might be
minimized, without compromising antithrombotic efficacy.
In this article, we will review new anticoagulant agents that
have the potential to be used for the prevention or treatment
of VTE, and will focus on the two drugs that have been
most extensively evaluated for these indications –
fondaparinux and ximelagatran.
New anticoagulant agents
Inhibitors of FVII/tissue factor initiation
of coagulation
NAPc2
Nematode anticoagulant protein c2 (NAPc2) is an 85-amino
acid protein with anticoagulant properties (Lee and Vlasuk
2003). Initially isolated from the hookworm, it has been
produced in a recombinant form, rNAPc2. Both the natural
and recombinant forms bind to a non-catalytic site on factor
X or Xa. NAPc2 bound to FXa then forms a quaternary
inhibitory complex with TF/FVIIa (Lee and Vlasuk 2003).
The ability to bind to FX results in NAPc2 having a
prolonged half-life of 50 hours.
In an open-label dose-ranging study, rNAPc2 has been
evaluated for prevention of VTE in patients undergoing
elective knee arthroplasty (Lee et al 2001). Administered
by subcutaneous injection every second day, an rNAPc2
dose of 3 µ/kg starting 1 hour after surgery was found to be
optimal and was associated with an overall rate of deep vein
thrombosis of 12.2%. Further trials of NAPc2 for this
indication have not been reported.
Indirect factor Xa inhibitors
Fondaparinux
Fondaparinux is a synthetic analogue of the critical
pentasaccharide sequence required for binding heparin
molecules to AT (Choay et al 1981; Walenga et al 1997). A
product of chemical engineering, it has minor modifications
from the naturally occurring pentasaccharide moiety,
improving the stability of the molecule and resulting in
enhanced binding to AT (Walenga et al 1997). Unlike UFH
and LMWH, it is a homogeneous product, and because it is
not derived from animal sources, there is no concern about
viral contamination.
Mechanism of action
In plasma, fondaparinux binds noncovalently (and therefore
reversibly) to its specific target molecule, AT, with 1:1
stoichiometry (Bauer 2003). The interaction with
fondaparinux results in a conformational change in the AT
molecule (Olson et al 1992) exposing the arginine containing
loop responsible for AT binding to factor Xa (Huntington et
al 2000). The improved affinity of AT for factor Xa when
bound to fondaparinux results in a 300-fold increase in the
Xa inhibitory effect of AT (Olson et al 1992). Once AT binds
factor Xa, fondaparinux is released due to a further
conformational change, allowing binding to other AT
molecules (Bauer 2003). Unlike other heparins,
fondaparinux is too short to provide the bridging between
AT and thrombin required to catalyze AT mediated inhibition
of thrombin (Olson et al 1992).
Although fondaparinux does not directly influence AT
mediated inhibition of thrombin, it does inhibit thrombin
generation when the coagulation cascade is triggered by
tissue factor (Beguin et al 1989; Lormeau and Herault 1993)
(Figure 1). The degree of inhibition of thrombin generation
has been shown to correlate directly with plasma antifactor
Xa activity (Lormeau and Herault 1995). As factor Xa is
protected from inhibition by AT-fondaparinux when bound
to factor V and phospholipid as part of the prothrombinase
complex (Beguin et al 1989; Brufatto et al 2003), the target
is likely to be free factor Xa prior to incorporation. In
contrast to unfractionated heparin, fondaparinux inhibits
thrombin generation in platelet-rich plasma (Beguin et al
1989; Gerotziafas et al 2004a), presumably because, unlike
other heparins, it does not demonstrate non-specific binding
to other plasma proteins, in particular platelet factor 4 (PF4)
(Bauer 2003; Gerotziafas et al 2004a).
The antithrombotic activity of fondaparinux has been
studied in animal models of venous thrombosis, and it was
found to be as effective as UFH and LMWH at inhibiting
thrombus formation and propagation (Herbert et al 1997;
Walenga et al 1997). The antithrombotic effect appears to
correlate closely with ex vivo antifactor Xa activity (Carrie
et al 1994). In three different animal models, bleeding was
not significantly increased in doses far exceeding
“therapeutic” levels (Herbert et al 1997; Walenga et al 1997).
Pharmacological considerations
Given subcutaneously, fondaparinux demonstrates 100%
bioavailability with peak plasma concentrations occurring
1.7 hours after dosing (Donat et al 2002). The drug half-lifeVascular Health and Risk Management 2005:1(1) 44
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in young healthy volunteers was found to be 17 hours
making once daily dosing feasible, and was independent of
the initial dose given. Steady state is obtained after the third
or fourth once daily dose with a 1.3-fold increase in peak
concentration and AUC (Donat et al 2002). The kidney is
the major route of clearance, with approximately 70% of
the initial dose recovered in the urine in an unchanged form
(Donat et al 2002). Peak plasma concentrations and AUC
are linearly correlated with dose and show minimal inter-
subject variability, obviating the need for monitoring drug
levels when renal function is normal (Boneu et al 1995).
Patients with reduced creatinine clearance, such as the
elderly, show higher peak drug levels and longer drug half-
life and may require dose adjustment (Boneu et al 1995;
Donat et al 2002).
Fondaparinux does not undergo hepatic metabolism, or
interact with other drugs that do so, and no pharmaco-
dynamic or pharmacokinetic interactions were seen with
warfarin, piroxicam, aspirin, or digoxin (Bauer 2003).
Although there is no data from administration to pregnant
human subjects, no evidence of placental transfer was seen
in a dually perfused human cotyledon with therapeutic
plasma concentrations (Lagrange et al 2002).
Monitoring
Routine monitoring of fondaparinux is not required.
However, estimation of antithrombotic activity may be
necessary when patients receiving treatment require urgent
invasive intervention. Fondaparinux does not prolong the
activated partial thromboplastin time (aPTT), activated
clotting time (ACT), or prothrombin time (PT), even in high
doses (Boneu et al 1995; Linkins et al 2002). Direct
measurement of antifactor Xa levels is therefore required.
Variability in results using different antifactor Xa assays
calibrated with different LMWH standards emphasizes the
need for a standardized assay using a fondaparinux reference
preparation (Depasse et al 2004).
Clinical trials
Prophylaxis trials
The efficacy and safety of fondaparinux for both the
prevention and treatment of VTE have been studied in a
number of large clinical trials. An initial dose-finding study
of fondaparinux for VTE prophylaxis in patients undergoing
total hip replacement (THR) was performed using confirmed
clinical or asymptomatic VTE and major bleeding as end
points. A clear dose effect on both efficacy and safety was
demonstrated, and a dose of 2.5 mg daily, commencing
6 hours after surgery, was identified as the probable optimal
dose regimen and was chosen for further evaluation in large
phase III trials (Turpie et al 2001).
Four multicentre, double-blind, randomized trials
comparing the efficacy and safety of fondaparinux with
enoxaparin in major orthopedic surgery have been
performed (Bauer et al 2001; Lassen et al 2002; Turpie et al
2002a; Eriksson and Lassen 2003) (Table 1). The EPHESUS
(Lassen et al 2002) and PENTATHLON 2000 (Turpie et al
2002a) trials enrolled patients undergoing elective THR; the
PENTHIFRA trial involved patients undergoing surgery for
hip fracture (Eriksson et al 2001); and PENTAMAKS trial
participants underwent elective knee replacement surgery
(TKR) (Bauer et al 2001). All trials used the fondaparinux
Table 1 Prophylactic trials of fondaparinux in major orthopedic surgery
Fondaparinux Control arm Fondaparinux Enoxaparin
Control arm dose rate of VTE rate of VTE major bleeding major bleeding
Trial of enoxaparin n % n % n % n %
Primary trials
EPHESUS 40 mg od
a 37/908 4.1
c 85/919 9.2 47/1140 4.1 32/1133 2.8
PENTATHLON 30 mg bidb 48/787 6.1 66/797 8.3 20/1128 1.8 11/1129 1.0
PENTHIFRA 40 mg od
a 52/626 8.3
d 119/624 19.1 18/831 2.2 19/842 2.3
PENTAMAKS 30 mg bid
b 45/361 12.5
d 101/363 27.8 11/517 2.1
c 1/517 0.2
PENTHIFRA PLUS Placebo only 3/208 1.4d 77/220 35.0 8/327 2.4 2/329 0.6
Meta-analysis
Turpie et al 2002a NA 182/2682 6.8
d 371/2703 13.7 96/3616 2.7
f 63/3621 1.7
Abbreviations: VTE, venous thromboembolism; od, once daily; bid, twice daily.
a Enoxaparin was commenced 12 hours before surgery with second injection given 12–24 hours after surgery.
b Enoxaparin was commenced 12–24 hours after surgery.
c p < 0.0001
d p < 0.001
e p = 0.006
f p = 0.008Vascular Health and Risk Management 2005:1(1) 45
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dose of 2.5 mg subcutaneously daily commencing
6 ± 2 hours postoperatively, although in the PENTHIFRA
study a dose was given 12 ± 2 hours prior to surgery if
surgery was delayed 24–48 hours after admission. The
enoxaparin regime used for comparison differed among
trials (Turpie et al 2003) (Table 1), with both treatments
given for 5–10 days postoperatively. The primary efficacy
end point of the trials was VTE, which included: (1)
asymptomatic DVT demonstrated by mandatory ascending
bilateral contrast venography of the legs performed on day
11 or within 48 hours of the last dose of trial drug; and (2)
symptomatic DVT or PE confirmed by objective testing
within 48 hours of the last dose of trial drug. The primary
safety end point was major bleeding up to day 11, defined
as fatal bleeding, bleeding that was intracranial, intraspinal,
into a critical organ, that required reoperation, or that did
not meet the preceding criteria but was associated with a
bleeding index of greater than 2 (the bleeding index
was calculated as the number of units of packed cells or
whole blood transfused plus prebleeding – postbleeding
hemoglobin in g/dL) (Turpie et al 2003).
The results of the trials are presented in Table 1. A meta-
analysis of these studies that included a total of 7344 subjects
showed a 55.2% (p < 0.001, 95% confidence interval (CI)
45.8–63.1) common odds reduction in the incidence of VTE
in favor of fondaparinux (Turpie et al 2002b). Although the
majority of these events were asymptomatic distal DVT
detected by venography, many of which are clinically
irrelevant, these are widely accepted as an appropriate
surrogate for clinically important outcomes (Turpie et al
2003). As fondaparinux was initiated sooner than enoxaparin
postoperatively, it is unclear if the superior efficacy is a result
of the drug or timing of the first postoperative dose (Hirsh
et al 2005). Major bleeding occurred more frequently in the
patient group receiving fondaparinux (p = 0.008), although
this was largely due to events with a bleeding index of 2 or
more, rather than clinically significant bleeding. A post hoc
analysis was performed and revealed a statistically
significant relationship between timing of fondaparinux dose
and bleeding, while no such relationship was seen for
efficacy; patients who received their first dose of
fondaparinux greater than 6 hours after surgery had a similar
rate of major bleeding to those receiving enoxaparin (Turpie
et al 2002b).
A single phase III trial has examined extended
prophylaxis with fondaparinux in patients undergoing hip
fracture surgery (Eriksson and Lassen 2003). All patients
received an initial 7 days of treatment with fondaparinux
and then were randomized to a further 3 weeks of
fondaparinux or placebo, with venography performed at the
end of study drug administration. Fondaparinux decreased
the rate of DVT from 35% to 1.4% (p < 0.001), with
symptomatic events decreasing from 2.7% to 0.3%
(p = 0.02). A small nonsignificant increase in major bleeding
was seen. This trial has led to approval of fondaparinux for
extended prophylaxis following surgery for hip fracture. The
results of trials of fondaparinux in general medical and
surgical patients have been reported in abstract form, with
fondaparinux appearing equivalent to dalteparin for VTE
prophylaxis following abdominal surgery, and not
surprisingly, superior to placebo at preventing VTE in
acutely ill medical patients (Hirsh et al 2005).
Treatment trials
Two trials have evaluated fondaparinux for initial treatment
of VTE (Buller et al 2003, 2004). The Matisse-DVT trial
compared daily subcutaneous fondaparinux (5.0 mg daily
if < 50 kg, 7.5 mg daily if 50–100 kg, 10 mg daily if > 100 kg)
with enoxaparin 1 mg/kg twice daily for the initial treatment
of symptomatic proximal DVT. Patients in both study arms
received the study drug for at least 5 days and until vitamin
K antagonist therapy resulted in an International Normalized
Ratio (INR) of ≥ 2 for two consecutive days. Treatment with
a vitamin K antagonist was continued for 3 months. The
fondaparinux regime had been determined by a previous
dose-finding study (Rembrandt 2000). After 3 months,
symptomatic recurrence occurred in 43/1098 (3.9%) and
45/1107 (4.1%) in the fondaparinux and enoxaparin groups,
respectively (95% CI of the absolute difference of 0.2%,
1.8 to –1.5%), with low and similar rates of major bleeding
in both groups. Fondaparinux was judged to be non-inferior
to enoxaparin with regards to both efficacy and safety.
In the Matisse-PE trial (Buller et al 2003), patients with
objectively diagnosed symptomatic PE were randomized
to initial treatment with either fondaparinux (5.0, 7.5, or
10 mg according to weight) by daily subcutaneous injection
or a continuous intravenous infusion of UFH (adjusted to
maintain an aPTT at 1.5–2.5 times control). Both were
continued for at least 5 days and were overlapped with a
vitamin K antagonist for at least 5 days and until the INR
was ≥ 2 on 2 consecutive days. Recurrent VTE developed
during the 3-month study period in 42/1103 (3.8%) and
56/1110 (5.0%) of patients receiving fondaparinux and
UFH, respectively (absolute difference of –1.2%, 95% CI
–3.0 to 0.5). Again, the rates of major bleeding were low
and not significantly different between treatment arms.Vascular Health and Risk Management 2005:1(1) 46
McRae and Ginsberg
Based on these results, fondaparinux appears to be as
effective and safe as UFH for treatment of PE.
Comparison of fondaparinux to conventional
anticoagulants
Fondaparinux appears to be as effective as LMWH for the
initial treatment of DVT, as effective as UFH for treatment
of PE, and more effective than LMWH for prevention of
VTE following orthopedic surgery. The decreased bleeding
rate seen in animal studies has not been reflected in clinical
studies, with the rate of significant bleeding comparable to
that with conventional antithrombotic agents, although it is
worth noting that five fatal bleeding episodes occurred in
patients randomized to fondaparinux in the Matisse-DVT
trial as opposed to none in the enoxaparin arm (Buller et al
2004). Like LMWH, it does not require laboratory
monitoring, and has the additional benefit of being less dose-
dependent on patient size, although dose was adjusted for
individuals at the extremes of body weight in both the
Matisse-DVT and Matisse-PE trials. Fondaparinux does not
cross react with sera from patients with HIT, and clinical
HIT has not yet been associated with its use (Bauer 2003).
Trials to date have excluded pregnant subjects and patients
with renal failure, and at present fondaparinux should not
be used in these patients groups. Unlike UFH, the
anticoagulant effect of fondaparinux is not reversed by
protamine sulfate (Hirsh et al 2005). Recombinant factor
VIIa (rFVIIa) has been shown to attenuate the antithrombotic
effect of fondaparinux in vitro and ex vivo (Bijsterveld et al
2002; Gerotziafas et al 2004b); however, its efficacy in
bleeding patients is unproven, and the current expense of
the drug is prohibitive. The decision to use fondaparinux
for either initial treatment of VTE or prophylaxis will
probably be influenced by the cost of the drug in comparison
to traditional agents in most healthcare settings, although
analyses using both UK and USA based models have found
it to be cost-effective for prophylaxis post major orthopedic
surgery.
Idraparinux
Idraparinux is an O-methylated, O-sulfated synthetic
analogue of the pentasaccharide molecule, with the chemical
changes resulting in a 30-fold increase in affinity for AT in
comparison to fondaparinux. As a result, the half-life of
idraparinux is 130 hours, making once weekly dosing
feasible. Like fondaparinux, idraparinux demonstrates
isolated dose-dependent antifactor Xa activity that correlates
directly with the ability of the drug to inhibit thrombin
generation in animal studies. Idraparinux was shown to be
an effective antithrombotic agent in animal models of venous
thrombosis. Due to the prolonged anticoagulant effect of
the drug, an effective reversal agent would be highly
desirable, particularly in bleeding patients or those who
require surgery or other invasive procedures. rFVIIa has been
shown to partially reverse the effect of the drug in vitro
(Bijsterveld et al 2004) although evidence of clinical utility
is lacking, and given the difference in half-lives, repeated
dosing of rFVIIa is likely to be required.
A phase II trial reported that a dose of idraparinux 2.5 mg
weekly was as effective as warfarin for the treatment of
proximal DVT, with patients receiving idraparinux having
a lower rate of bleeding (The PERSIST investigators 2004).
Both groups initially received enoxaparin. Whilst higher
doses of idraparinux showed similar efficacy, a dose
response for bleeding was seen. Therefore the dose of 2.5 mg
weekly was chosen for the ongoing van Gogh DVT and PE
phase III trials.
Direct Xa inhibitors
Novel anticoagulant drugs that bind directly to factor Xa,
inhibiting its procoagulant activity, are in the early stages
of clinical development. Razaxaban (DPC 906), an orally
bioavailable, nonpeptidic synthetic factor Xa inhibitor, at a
dose of 25 mg 12 hourly appeared to be at least as effective
and safe as enoxaparin for VTE prophylaxis following knee
replacement surgery (Lassen et al 2003). A similar agent
DX-9065a has undergone trials in coronary artery disease
but not VTE (Hirsh et al 2005).
Direct thrombin inhibitors
Ximelagatran
Ximelagatran (Exanta™) is a new oral prodrug of
melagatran, a synthetic direct thrombin inhibitor. Due to
the minimal need for blood monitoring and its oral
formulation, it has the potential to replace warfarin as the
drug of choice for long-term anticoagulation. Results from
phase III trials of Ximelagatran for various clinical
indications have recently become available.
Mechanism of action
Melagatran is a dipeptide molecule that binds reversibly to
the active site of thrombin, resulting in potent, AT
independent, competitive inhibition of thrombin activity
(Weitz and Crowther 2002; Gustafsson and Elg 2003).Vascular Health and Risk Management 2005:1(1) 47
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Melagatran is not orally absorbed, and therefore a lipophilic
derivative, ximelagatran, was developed (Gustafsson and
Elg 2003). Ximelagatran is rapidly converted to its active
form, via two intermediate metabolites, within hours of oral
administration (Weitz and Crowther 2002).
Unlike the heparin/AT complex, melagatran has been
shown to inhibit both fluid-phase thrombin and thrombin
bound to fibrin clot, a property that theoretically might result
in more effective antithrombotic activity (Weitz and
Crowther 2002; Klement et al 2003). Melagatran has been
shown not only to inhibit thrombin activity, but also tissue
factor initiated thrombin generation in a dose-dependent
manner (Bostrom et al 2003, 2004). The antithrombotic
efficacy of melagatran has been demonstrated in animal
models of venous thrombosis (Eriksson, Carlsson, et al
1997; Weitz and Crowther 2002). Melagatran has a
shallower dose-response curve than warfarin, with a 10-fold
increase in dose of melagatran producing the same increase
in antithrombotic activity as a doubling of the dose of
warfarin (Elg et al 1999). As melagatran at therapeutic doses
only marginally increases bleeding time in animal models,
in comparison to significant changes seen with equivalent
doses of warfarin and UFH, it appears to have a wider
therapeutic window than conventional anticoagulants (Elg
et al 1999; Klement et al 2003).
Pharmacological considerations
Ximelagatran demonstrates 20% oral bioavailability that is
minimally affected by food intake, with peak plasma
melagatran concentrations observed 1.5–2 hours after oral
administration (Gustafsson and Elg 2003). After oral
administration of ximelagatran, the plasma half-life of
melagatran is approximately 3 hours, resulting in a need
for twice daily dosing. As drug elimination is predominantly
renal, the half-life is prolonged in individuals with reduced
creatinine clearance (Gustafsson and Elg 2003). Minimal
inter-individual variability is seen in the pharmacokinetics
of ximelagatran in healthy volunteers, with the coefficient
of variation in plasma melagatran levels being 20% after
oral administration of ximelagatran (Gustafsson and Elg
2003). Peak plasma concentrations and AUC were linearly
related to dose in both healthy volunteers (Gustafsson et al
2001) and patients undergoing major surgery (Eriksson,
Arfwidsson, et al 2002). Obesity, ethnicity, and drugs
inhibiting the cytochrome P450 isoenzyme activity do not
influence ximelagatran pharmacokinetics (Gustafsson and
Elg 2003).
Effect on laboratory coagulation parameters
The reproducible pharmacokinetic profile of ximelagatran
suggests that routine laboratory monitoring during treatment
is not required, a presumption that has been supported by
the results of subsequent trials using fixed dose therapy.
However, estimation of anticoagulant activity may still be
required on occasions. In platelet poor plasma from
volunteers, melagatran doubled thrombin, prothrombin,
and aPTT clotting times at concentrations of 0.010, 2.2,
and 0.59 µmol/L, respectively. In patients undergoing
orthopedic surgery or being treated for DVT or PE,
melagatran plasma levels show a nonlinear correlation with
prolongation of the aPTT, with doubling of aPTT seen at a
plasma concentration of 0.6 µmol/L (Eriksson, Arfwidsson,
et al 2002; Wahlander et al 2002; Gustafsson and Elg 2003).
At the mean maximum plasma concentration of between
0.1–0.3 µmol/L obtained with prophylactic treatment, the
aPPT was prolonged approximately 1.5-fold (Eriksson,
Arfwidsson, et al 2002)
Clinical trials
Prophylaxis trials
There are two groups of trials of ximelagatran for VTE
prophylaxis following major orthopedic surgery due to the
different practices of preoperative initiation of anticoagulant
therapy in Europe, and postoperative commencement in
North America. The two groups of trials will be discussed
separately.
Trials performed in Europe studied the use of
subcutaneous melagatran followed by oral ximelagatran
for orthopedic prophylaxis, with melagatran normally
commenced preoperatively. A range of doses of melagatran
(1–4 mg bid (twice daily)) commencing preoperatively,
followed by ximelagatran (6–24 mg bid) were shown to have
acceptable safety in an initial phase II study (Eriksson,
Arfwidsson, et al 2002). A larger phase II study, METHRO
II, and phase III studies, METHRO III and EXPRESS, were
then performed (Eriksson, Bergqvist, et al 2002; Eriksson
et al 2003a, 2003b). The primary efficacy end point in these
trials was the rate of total VTE including: (1) asymptomatic
DVT demonstrated by mandatory bilateral venography of
the legs 7–12 days after surgery; and (2) symptomatic DVT
or PE confirmed by objective testing, with some trials also
including unexplained death (Eriksson et al 2003a, 2003b).
Severe bleeding, defined as bleeding involving a critical site
(intracranial, intraocular, intraspinal, or retroperitoneal) or
excessive bleeding as determined by an investigator, wasVascular Health and Risk Management 2005:1(1) 48
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the primary safety end point. EXPRESS also included
bleeding not from the operation wound that required ≥ 2 unit
transfusion of blood and fatal bleeding (Eriksson et al
2003b).
Table 2 summarizes the results of these trials. All trials
involved patients undergoing THR and TKR, with
prophylaxis being given for 8–11 days postoperatively until
mandatory venography. A melagatran/ximelagatran dose-
dependent decrease in VTE was shown in METHRO II. The
regime of melagatran 3 mg bid commenced immediately
before surgery and continued for 1–3 days postoperatively
until oral therapy with ximelagatran 24 mg bid could be
commenced was found to have maximum efficacy. This
regime was significantly more effective at preventing VTE
than dalteparin started preoperatively, with a nonsignificant
increase in bleeding seen (Eriksson, Bergqvist, et al 2002).
In an attempt to limit the risk of bleeding, METHRO III
utilized the same drug doses, but started melagatran 4–12
hours postoperatively. Whilst a similar bleeding rate to
enoxaparin was seen, the rate of VTE in subjects given
ximelagatran was the same as patients receiving enoxaparin
(Eriksson et al 2003a). It appeared that the timing of starting
melagatran, ie, pre- or postoperatively, influenced efficacy.
In an attempt to maximize the benefit to risk ratio, the
EXPRESS trial used a reduced dose of melagatran of 2 mg
immediately prior to surgery, followed by 3 mg on the
evening of surgery, switching to oral ximelagatran 24 mg
bid the next day (Eriksson et al 2003b). This protocol was
associated with a significant reduction in total and major
(proximal DVT and/or PE) VTE in comparison to
enoxaparin commenced preoperatively, with no increase in
bleeding seen in patients undergoing TKR, but an increased
rate of noncritical bleeding in patients undergoing THR
receiving melagatran/ximelagatran. In addition, one case of
fatal intraoperative hemorrhage, a rare event during
orthopedic surgery, occurred in the ximelagatran group
following iatrogenic injury to the iliac and femoral vessels.
Trials evaluating ximelagatran for orthopedic
prophylaxis in North America used a twice-daily oral regime
commencing 12–24 hours postoperatively or the next
morning after surgery. An initial dose-ranging study
evaluating 8–24 mg twice daily found the highest dose to
Table 2 Prophylactic trials of melagatran (Mel)/ximelagatran (XM) in major orthopedic surgery
Total VTE Major VTE Severe bleeding Mean blood
Trial Treatment regime n % n % n % loss (mL)
European trials
METHRO II Mel 3 mg bid then XM 24 mg bida 43/285 15.1c 7/285 2.5 18/360 5.0 1331
DAL 5000 IU od 87/308 28.2 20/308 6.5 9/381 2.4 1165
METHRO III Mel 3 mg bid then XM 24 mg bid
b 355 /1146 31.0 65/1144 5.7 20/1399 1.4 1115
Enoxaparin 40 mg od 306/1122 27.3 69/1113 6.2 23/1389 1.7 1100
EXPRESS Mel 2 mg pre-op, 3 mg post-op then
XM 24 mg bid
a 231/1141 20.3
d 26/1138 2.3 46/1378 3.3
e 1015
Enoxaparin 40 mg od 315/1184 26.6 74/1178 6.3 16/1387 1.2 913
North American trials
Francis et al 2002 XM 24 mg bid 53/276 19.2 9/274 3.3 6/345 1.7 773
WAR (Target INR 1.8–3.0) 67/261 25.7 13/258 5.0 3/330 0.9 741
EXULT A XM 24 mg bid 153/614 24.9 15/606 2.5 6/757 0.8 846
XM 36 mg bid 128/629 20.3
f 17/629 2.7 6/769 0.8 840
WAR (Target INR 1.8–3.0) 168/608 27.6 25/603 4.1 5/759 0.7 861
EXULT B XM 36 mg bid 221/982 22.5
g 38/982 3.9 115/1151 1.0 –
WAR (Target INR 1.8–3.0) 308/967 31.9 40/967 4.1 46/1148 0.4 –
Colwell, Berkowitz, 
Davidson, et al 2003 XM 24 mg bid 62/782 7.9
h 28/782 3.6 7/906 0.8 964
Enoxaparin 30 mg bid 36/775 4.6 9/774 1.2 8/910 0.9 958
NOTE: Dashes indicate data not available.
Abbreviations: Mel, melagatran; XM, ximelagatran; DAL, dalteparin; WAR, warfarin; VTE, venous thromboembolism; bid, twice a day; od, once daily; INR, International
Normalized Ratio.
a Melagatran dose commenced immediately before surgery.
b Melagatran commenced 4–12 hours postoperatively.
c p = 0.0001
d p < 0.0004
e p = 0.0002
f p = 0.003
g p < 0.001
h p = 0.009Vascular Health and Risk Management 2005:1(1) 49
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be the most effective in patients undergoing TKR, with
ximelagatran 24 mg bid showing a nonsignificant decrease
in VTE in comparison to postoperative enoxaparin 30 mg
12 hourly, with no difference seen in bleeding rates (Heit et
al 2001). Further phase III studies were then performed and
utilized either this dose or 36 mg bid. The primary efficacy
end point in these trials was the same as the above studies,
with death also included in the primary efficacy end point
in the EXULT A and B trials (Colwell, Berkowitz, Comp,
et al 2003; Francis, Berkowitz, et al 2003). The major safety
end point was major bleeding, defined as fatal bleeding,
critical bleeding (as defined above), requiring reoperation,
or bleeding associated with a bleeding index of ≥ 2 (as
previously defined).
The trials are summarized in Table 2. Treatment was
given for 7–12 days in all studies, and all were double-blind,
randomized controlled trials. Three trials compared
ximelagatran with warfarin for VTE prophylaxis in patients
undergoing TKR. Francis et al (2002) reported a
significantly lower incidence of total VTE and a trend
towards less major VTE in patients receiving ximelagatran
24 mg bid, compared with patients receiving warfarin
prophylaxis commencing at a minimum dose of 5 mg on
the evening of surgery, then titrated to an INR of 1.8–3.0.
No significant increase in bleeding was seen. The efficacy
of a higher dose of ximelagatran, 36 mg bid, was assessed
in EXULT A and was found to be more effective (absolute
risk reduction of 7.3%, 95% CI 2.5–12.0) than warfarin for
preventing VTE, with no excess of bleeding seen (Francis,
Berkowitz, et al 2003). The improved efficacy of
ximelagatran 36 mg bid in comparison to warfarin was
confirmed by EXULT B, reported recently in abstract form
(Colwell, Berkowitz, Comp, et al 2003).
Results from the phase II study suggested that
ximelagatran 24 mg bid commencing postoperatively might
be effective for prevention of VTE in patients undergoing
THR (Heit et al 2001). However, this dose of ximelagatran
was shown to have inferior efficacy in comparison to
enoxaparin 30 mg 12 hourly in patients undergoing THR,
with the rate of major bleeding being similar (Colwell,
Berkowitz, Davidson, et al 2003).
Treatment of VTE
THRIVE I was a randomized dose-finding study evaluating
the efficacy and tolerability of ximelagatran for the initial
treatment of DVT, in comparison to dalteparin followed by
warfarin (Eriksson, Wahlander, et al 2003). Patients were
randomized to receive ximelagatran (24, 36, 48, or 60 mg
twice daily), or dalteparin 200 U kg–1 subcutaneously once
daily and warfarin adjusted to achieve an INR of between 2
and 3. Efficacy was determined by comparing paired
venograms obtained prior to treatment commencing and at
the end of the two week treatment period. Regression of
thrombus was seen in 69% of patients treated with
ximelagatran and 69% of patients treated with dalteparin
and warfarin, with no significant difference in response rate
seen among treatment groups. Ximelagatran was well
tolerated and appeared to be an effective agent for treatment
of VTE.
The clinical efficacy of ximelagatran in extended
secondary prevention of VTE was then assessed in THRIVE
III, a multicentre, randomized controlled trial (Schulman et
al 2003). After completion of six months of anticoagulant
therapy for objectively confirmed DVT or PE, patients were
randomized to receive ximelagatran 24 bid or placebo twice
daily for a period of 18 months. The primary efficacy end
point was symptomatic, objectively-confirmed recurrent
VTE occurring during the study period. As compared with
placebo, ximelagatran significantly reduced the rate of
recurrent VTE (p < 0.001), with the estimated cumulative
risk of recurrence after 18 months of treatment being 2.8%
in the ximelagatran group and 12.6% in the placebo group.
The hazard ratio for the ximelagatran group for major
bleeding in comparison to placebo was 1.16 (95% CI
0.35–3.80). Asymptomatic elevation of alanine amino-
transferase levels to more than three times the upper limit
of normal was more frequent in individuals receiving
ximelagatran than placebo, with the estimated cumulative
risk of such an elevation by 18 months being 6.4% in patients
receiving ximelagatran, compared with 1.2% in those
receiving placebo. At the last observation during the study,
liver enzyme levels had normalized in all but 4 of 37 affected
patients (two of whom had known hepatitis predating
commencement of ximelagatran). The time to normalization
was similar regardless of whether ximelagatran was
continued (median time 84 days), or discontinued (median
time 128 days).
The results of trials of ximelagatran for the initial
treatment of acute DVT with or without PE were recently
presented in abstract form (Francis, Ginsberg, et al 2003).
In a randomized, double-blind, double-dummy trial, patients
with acute symptomatic DVT were randomized to receive
either ximelagatran 36 mg bid for six months, or
subcutaneous enoxaparin 1 mg/kg bid and warfarin, with
enoxaparin given for a minimum of 5 days and until the
INR was ≥ 2 for at least for 48 hours, and warfarin (target
INR 2.0–3.0) continued for six months. Ximelagatran wasVascular Health and Risk Management 2005:1(1) 50
McRae and Ginsberg
shown to be non-inferior to enoxaparin/warfarin for
prevention of recurrent VTE, with a trend towards less major
bleeding in the ximelagatran group. The incidence of
elevation of alanine aminotransferase levels above three
times the upper limit of normal was 9.6% in patients
receiving ximelagatran, versus 2.0% in those treated with
enoxaparin/warfarin. Follow-up data on subsequent
normalization or otherwise of liver enzyme levels in these
individuals has not as yet been published.
Comparison of ximelagatran to conventional
anticoagulants
Ximelagatran appears to be an effective agent for both
prevention and treatment of VTE. At doses studied, when
used alone as an oral agent it has superior efficacy to warfarin
for preventing VTE post TKR, but inferior efficacy when
used for VTE prevention following THR. The risk of
bleeding appears equivalent, and it has the additional benefits
over warfarin of rapid onset of action, lack of interaction
with food and other drugs, and predictable pharmaco-
kinetics, removing the need for drug monitoring. Although,
unlike warfarin, a clinically tested antidote is not yet
available, the shorter half-life of ximelagatran may minimize
the requirement for reversal of its anticoagulant effect.
Activated prothrombin complex concentrates have been
shown to reverse melagatran induced prolongation of
bleeding times in animal models, and may prove to have
clinical utility.
When compared with standard LMWH regimes,
subcutaneous melagatran commenced preoperatively
followed by ximelagatran appeared to have improved
efficacy in patients undergoing either THR or TKR surgery,
although bleeding was increased in the THR subjects. The
decision to choose melagatran/ximelagatran over LMWH
may come down to individual assessment of bleeding and
VTE risk. The potential risk of HIT associated with LMWH
is avoided by melagatran. Ximelagatran may prove to be an
ideal agent for extended prophylaxis following orthopedic
surgery, given its oral formulation and lack of need for
monitoring.
Ximelagatran has also shown efficacy in the primary
treatment of acute VTE, and in secondary prophylaxis
following an acute event. The advantages of the drug over
warfarin, as listed above, may lead to it becoming the agent
of choice for these indications. However, concern currently
exists with regards to the development of elevated
transaminase levels to a level of above three times normal
in 5%–10% of individuals receiving ximelagatran for greater
than one month (Francis, Ginsberg, et al 2003; Olsson 2003;
Schulman et al 2003) The rate of elevation of liver
aminotransferase levels was higher in individuals receiving
the higher dose of ximelagatran in the THRIVE treatment
(36 mg bid) trial, than those individuals in THRIVE III
(24 mg bid), suggesting a possible dose relationship. Against
this, the rate of elevation of alanine aminotransferase levels
to above three times normal in SPORTIF III (Olsson 2003)
a trial in which patients with atrial fibrillation received
ximelagatran 36 mg bid, was 6%, a similar rate to that seen
with the lower dose in THRIVE III. Ongoing trials require
discontinuation of ximelagatran in participants who develop
marked or persistent elevations of transaminases; this side
effect may result in the need for routine monitoring of liver
function tests if ximelagatran is continued for more than
30 days, negating some of the benefit of the lack of need
for therapeutic monitoring. Concerns with regards to liver
toxicity contributed to the Food and Drug Administration
(FDA) decision to recently reject an initial application for
approval of ximelagatran for prophylactic and treatment
indications (Anonymous 2004).
Other direct thrombin inhibitors
Hirudin, bivalirudin, and argatroban are all direct thrombin
inhibitors which unlike ximelagatran, require parenteral
administration (Weitz and Crowther 2002). Hirudin was
originally isolated from the medicinal leech and is the
prototypical direct thrombin inhibitor. It binds bivalently to
the active site and exosite 1 of thrombin in an essentially
irreversible manner (Bates and Weitz 2003). A recombinant
desulfated form of hirudin, lepirudin, is commercially
available. Bivalirudin is a 20 amino acid synthetic molecule,
which like hirudin, binds thrombin bivalently (Weitz and
Crowther 2002). Once bound to thrombin, bivalirudin
undergoes cleavage leading to dissociation of its amino-
terminal from the active site of thrombin, with the carboxy-
terminal remaining only weakly bound to exosite 1 (Witting
et al 1992). This causes bivalirudin inhibition of thrombin
to be competitive and reversible, which, combined with a
shorter half-life (25 minutes compared with 60 minutes after
intravenous infusion), may result in bivalirudin having
improved safety compared with hirudin (Bates and Weitz
2003). Argatroban is a small synthetic, arginine derivative
that binds reversibly to the active site of thrombin, resulting
in competitive inhibition of thrombin activity. The plasma
half-life of argatroban is 45–60 minutes when givenVascular Health and Risk Management 2005:1(1) 51
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intravenously, with metabolism being hepatic unlike
lepirudin bivalirudin which undergoes renal clearance (Weitz
and Crowther 2002).
Lepirudin and argatroban have received FDA approval
for treatment of HIT and have been shown to be effective in
comparison to historical controls in reducing morbidity and
mortality, supporting the central role of thrombin in the
pathogenesis of this condition (Warkentin 2003). There is
also anecdotal evidence supporting the use of bivalirudin
for this condition. For details with regards to treatment
regimes, readers are referred to a recent review (Warkentin
2003). Despite phase III trial data showing recombinant
hirudin to have superior efficacy and similar safety to UFH
and LMWH for prevention of VTE following hip surgery
(Eriksson, Ekman, et al 1997; Eriksson, Wille-Jorgensen,
et al 1997), and promising phase II data for bivalirudin for
the same indication (Ginsberg et al 1994), neither agent is
currently marketed or being developed for this indication.
Drugs potentiating the protein C
anticoagulant pathway
Soluble thrombomodulin
Normally located on endothelial cells, thrombomodulin is
a transmembrane protein that forms a 1:1 complex with
thrombin, with the interaction inducing a conformational
change in thrombin. This results in inhibition of the ability
of thrombin to cleave fibrinogen and activate FV, FXIII,
and platelets, but also results in a 1000-fold increase in its
efficacy as an activator of protein C (Dittman and Majerus
1990). Soluble thrombomodulin is a functionally active,
truncated form of the protein that has been isolated from
human blood (Dittman and Majerus 1990). A recombinant
form of soluble thrombomodulin (ART-123) with a half-
life of 2–3 days has been evaluated for VTE prophylaxis
following hip arthroplasty in a dose-finding study (Kearon
et al 2003). A regime of 0.3 mg/kg subcutaneously 2–4 hours
after surgery, followed by the same dose on day 5, was
associated with a rate of VTE of 4.3% (including events
detected by mandatory venography), and an incidence of
major bleeding of 1.6%. A single higher dose following
surgery demonstrated increased efficacy but also an
increased incidence of bleeding.
Conclusions and future directions
After many years of limited therapeutic options for both
initial and extended antithrombotic therapy for VTE, new
anticoagulants with proven efficacy have become available
to the practicing clinician, with others likely to follow in
the near future. The clinical development of fondaparinux
and ximelagatran is furthest advanced, with both drugs
having been shown to be effective treatment for both VTE
prevention and prophylaxis. Neither drug requires routine
monitoring to maximize efficacy and safety, an advantage
over traditional antithrombotic agents that will be embraced
by both patient and clinician alike. As yet, clinical data has
not consistently supported the reduced risk of bleeding seen
in animal studies with many new anticoagulant drugs.
Ultimately, cost considerations, both individual and
institutional, will influence the degree to which these new
drugs are accepted as standard care.
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